Measuring amyloid and predicting tau status using a single amyloid PET study would be
valuable for assessing brain AD pathophysiology. We hypothesized that early-frame amyloid …

Accurate measurement of amyloid-b (Ab) PET tracer retention has become an increasingly
important feature of neuroimaging research in Alzheimer disease (AD). Although initial Ab …

629 Objectives: PET tracers for tau pathology in Alzheimer's disease (AD) are of increasing
interest as diagnostics and as markers of disease severity. However, there have been few …

Tau protein aggregations are a hallmark of amyloid-associated Alzheimer disease and
some forms of non–amyloid-associated frontotemporal lobar degeneration. In recent years …

The advent of PET ligands that bind tau pathology has enabled the quantification and
visualization of tau pathology in aging and in Alzheimer disease (AD). There is strong …

Purpose Characteristic features of amyloid-PET (A), tau-PET (T), and FDG-PET (N) can
serve for the A/T/N classification of neurodegenerative diseases. Recent studies showed …

Purpose Several radiotracers that bind to fibrillar amyloid-beta in the brain have been
developed and used in various patient cohorts. This study aimed to investigate the …

Recently, AmyloidIQ was introduced as a new canonical image-based algorithm to quantify
amyloid PET scans and demonstrated increased power over traditional SUV ratio (SUVR) …

Purpose [18 F] MK-6240, a second-generation tau PET tracer, is increasingly used for the
detection and the quantification of in vivo cerebral tauopathy in Alzheimer's disease (AD) …

1182 Objectives: Tau PET imaging has played a key role in assessing tau pathology
associated with Alzheimer disease (AD) in vivo. Standard methods of evaluation are …